Prognostic Value of MiR-17-5p in Cancers: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jun 29

PMID 29950859

Citations 8

Authors

Weihao Kong

Yusheng Cheng

Hao Liang

Qiangxing Chen

Cuicui Xiao

Kun Li

Zenan Huang

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Studies have shown that miR-17-5p plays an important role in the development of cancer. The aim of this meta-analysis was to quantitatively analyze the association of miR-17-5p with prognosis in various cancers.

Materials And Methods: We searched the PubMed, EMBASE, Web of Science, and Cochrane library databases for relevant studies through August 2017. The prognostic data and clinico-pathological features of overall survival (OS) and disease-free survival (DFS) were extracted to investigate the association between miR-17-5p expression and tumor prognosis. In addition, odds ratios (ORs) were used to assess the correlations between miR-17-5p expression and clinicopathological characteristics.

Results: A total of ten studies were incorporated into this systematic review, and we found that high miR-17-5p expression can predict poor OS for malignancies (combined hazard ratio [HR]=1.87; 95% confidence interval [CI], 1.37-2.55; =0.000) as well as poor DFS (combined HR=1.60; 95% CI, 1.05-2.44; =0.027). Further subgroup analyses suggested that high miR-17-5p expression was related to poor OS in Asian patients (combined HR=1.92; 95% CI, 1.37-2.71; =0.000) and the serum/plasma sample source subgroup (combined HR=2.13; 95% CI, 1.36-3.31; =0.001). The combined OR indicated that the expression of miR-17-5p was associated with lymph node invasion (OR=1.28; 95% CI, 1.05-1.56; =0.016) and venous invasion (OR=1.92; 95% CI, 1.40-2.63; =0.000).

Conclusion: Elevated expression of miR-17-5p suggested a poor prognosis in cancer patients and may serve as a new tumor marker to monitor cancer development and progression.

Citing Articles

Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses.

Mosharaf M, Alam K, Gow J, Mahumud R BMC Geriatr. 2023; 23(1):767.

PMID: 37993790 PMC: 10666371. DOI: 10.1186/s12877-023-04457-1.

Downregulation of CSF-derived miRNAs miR-142-3p and miR-17-5p may be associated with post-dural puncture headache in pregnant women upon spinal anesthesia.

Yucel D Braz J Anesthesiol. 2021; 72(4):493-499.

PMID: 34563560 PMC: 9373468. DOI: 10.1016/j.bjane.2021.08.016.

High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients.

Stoen M, Andersen S, Rakaee M, Pedersen M, Ingebriktsen L, Bremnes R Sci Rep. 2021; 11(1):13864.

PMID: 34226620 PMC: 8257715. DOI: 10.1038/s41598-021-93208-6.

Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients.

Sur D, Balacescu L, Cainap S, Visan S, Pop L, Burz C Front Oncol. 2021; 11:651380.

PMID: 34084747 PMC: 8167052. DOI: 10.3389/fonc.2021.651380.

Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.

Swellam M, Bakr N, El Magdoub H, Hamza M, El Arab L J Mol Neurosci. 2020; 71(4):836-844.

PMID: 32989634 DOI: 10.1007/s12031-020-01706-5.

References

Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L . Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012; 5(6):1514-20. DOI: 10.3892/mmr.2012.828. View

Shen J, Hung M . Signaling-mediated regulation of MicroRNA processing. Cancer Res. 2015; 75(5):783-91. PMC: 4348149. DOI: 10.1158/0008-5472.CAN-14-2568. View

Diaz R, Silva J, Garcia J, Lorenzo Y, Garcia V, Pena C . Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008; 47(9):794-802. DOI: 10.1002/gcc.20580. View

Svoronos A, Engelman D, Slack F . OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 2016; 76(13):3666-70. PMC: 4930690. DOI: 10.1158/0008-5472.CAN-16-0359. View

Fang L, Li H, Wang L, Hu J, Jin T, Wang J . MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014; 5(10):2974-87. PMC: 4102784. DOI: 10.18632/oncotarget.1614. View

Qu Y, Zhang H, Duan J, Liu R, Deng T, Bai M . MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer. Oncotarget. 2016; 7(22):33286-96. PMC: 5078094. DOI: 10.18632/oncotarget.8946. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

Chen L, Jiang M, Yuan W, Tang H . miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg. 2012; 25(3):156-61. DOI: 10.3109/08941939.2011.618523. View

Kleemann M, Bereuther J, Fischer S, Marquart K, Hanle S, Unger K . Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis. Oncotarget. 2016; 8(12):18773-18791. PMC: 5386646. DOI: 10.18632/oncotarget.13095. View

10.

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

11.

Zheng J, Dong P, Gao S, Wang N, Yu F . High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology. 2012; 60(123):549-52. DOI: 10.5754/hge12754. View

12.

Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y . miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology. 2010; 51(5):1614-23. DOI: 10.1002/hep.23566. View

13.

Zhang J, Xu Y, Gao Y, Chen C, Zheng Z, Yun M . Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017; 16(1):18. PMC: 5259972. DOI: 10.1186/s12943-017-0586-y. View

14.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

15.

Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C . Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol. 2012; 30(1):353. DOI: 10.1007/s12032-012-0353-2. View

16.

Zakrzewska M, Fendler W, Zakrzewski K, Sikorska B, Grajkowska W, Dembowska-Baginska B . Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. PLoS One. 2016; 11(7):e0158464. PMC: 4938415. DOI: 10.1371/journal.pone.0158464. View

17.

Liu D, Dong L, Liu Y, Wen D, Gao D, Sun H . A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma. Tumour Biol. 2015; 37(4):5039-47. DOI: 10.1007/s13277-015-4355-5. View

18.

Yu J, Ohuchida K, Mizumoto K, Fujita H, Nakata K, Tanaka M . MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 2010; 10(8):748-57. DOI: 10.4161/cbt.10.8.13083. View

19.

Ahmadi S, Sharifi M, Salehi R . Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation. Cancer Gene Ther. 2016; 23(7):199-205. DOI: 10.1038/cgt.2016.10. View

20.

Wang W, Zhang L, Zheng K, Zhang X . miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism. Oncol Rep. 2016; 35(3):1473-82. DOI: 10.3892/or.2016.4542. View